Home » Topics » BioWorld Science

BioWorld Science
RSS

New phase II trial investigates CFZ-533 in pediatric and young adults with type 1 diabetes

Dec. 13, 2019

OrphoMed begins phase II study of ORP-101 in IBS-D

Dec. 13, 2019

C&C Research Laboratories identifies STAT3 inhibitors

Dec. 13, 2019

Study confirms target engagement with BTRX-335140 in healthy volunteers

Dec. 13, 2019

Merck & Co. describes new IDO1 inhibitors

Dec. 13, 2019

DYRK2 is a critical checkpoint in the control of leukemia stem cell maintenance

Dec. 13, 2019

Innovent Biologics presents PI3K inhibitors

Dec. 13, 2019

Adlai Nortye divulges new CSF1R inhibitors

Dec. 13, 2019

Antabio SAS patents new antibacterial compounds

Dec. 13, 2019

DPP8 may be a target for multiple myeloma therapy by inducing apoptotic cell death

Dec. 13, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.